Centessa Pharmaceuticals PLC (CNTA) — 8-K Filings

8-K Filings (18)

• Centessa Pharmaceuticals Reports Director/Officer Changes — Dec 11, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on December 11, 2025, reporting events as of December 5, 2025. The filing covers the departure of directors or certain
• Centessa Pharmaceuticals Files 8-K — Nov 24, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on November 24, 2025, reporting other events and financial statements. The filing does not contain specific financial
• Centessa Pharmaceuticals Enters Material Definitive Agreement — Nov 13, 2025 Risk: medium
  Centessa Pharmaceuticals plc entered into a material definitive agreement on November 11, 2025. The company also reported other events and filed financial state
• Centessa Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 20, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on June 20, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's c
• Centessa Pharmaceuticals Files 8-K — Jun 17, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on June 17, 2025, reporting other events and financial statements as of June 16, 2025. The filing details the company'
• Centessa Pharmaceuticals Announces Board and Officer Changes — May 29, 2025 Risk: low
  Centessa Pharmaceuticals plc announced on May 27, 2025, changes in its board of directors and executive officers. The company also reported on compensatory arra
• Centessa Pharmaceuticals Files 8-K on Financials — Mar 24, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on March 24, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Centessa Pharmaceuticals Enters Material Definitive Agreement — Feb 21, 2025 Risk: medium
  Centessa Pharmaceuticals plc entered into a material definitive agreement on February 14, 2025. The filing does not disclose the specific nature or counterparty
• Centessa Pharmaceuticals Files 8-K — Jan 8, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on January 8, 2025, reporting a current event. The filing details the company's incorporation in England and Wales and
• Centessa Pharmaceuticals Enters/Terminates Agreements, Incurs Obligation — Dec 30, 2024 Risk: medium
  Centessa Pharmaceuticals plc entered into a material definitive agreement and terminated another on December 30, 2024. The company also incurred a direct financ
• Centessa Pharmaceuticals Enters Material Definitive Agreement — Sep 13, 2024 Risk: medium
  On September 12, 2024, Centessa Pharmaceuticals plc entered into a material definitive agreement. The company also reported other events and filed financial sta
• Centessa Pharmaceuticals Files 8-K with Corporate Updates — Sep 10, 2024 Risk: low
  Centessa Pharmaceuticals plc announced on September 10, 2024, that it is filing a Form 8-K. The filing provides updated information regarding the company's corp
• Centessa Pharmaceuticals Files 8-K on Shareholder Votes — Jun 25, 2024 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on June 25, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specif
• Centessa Pharmaceuticals CMO Departs; Severance Package Detailed — Jun 10, 2024 Risk: medium
  Centessa Pharmaceuticals plc announced on June 5, 2024, the departure of its Chief Medical Officer, Dr. Andrew Allen, effective immediately. The company also di
• Centessa Pharmaceuticals Enters Material Agreement — Apr 24, 2024 Risk: medium
  Centessa Pharmaceuticals plc announced on April 23, 2024, that it has entered into a material definitive agreement. The company also reported its results of ope
• Centessa Pharmaceuticals Files 8-K — Apr 22, 2024 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on April 22, 2024, reporting on other events and financial statements. The filing does not contain specific financial
• Centessa Confirms Ordinary Shares Listed on Nasdaq Under CNTA — Feb 9, 2024 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on February 9, 2024, to update its registered securities. The filing clarifies that its Ordinary shares, with a nomina
• Centessa Pharma Confirms Ordinary Shares Listed on Nasdaq — Jan 9, 2024
  Centessa Pharmaceuticals plc filed an 8-K on January 9, 2024, to update its registration of securities. The company clarified that its Ordinary shares, with a n

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX